Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710338 | 0.90 | AGTR2 (0.51) | AGTR2AGTR1 | |
| SCHEMBL4181608 | 0.84 | AGTR2 (0.46) | AGTR2AGTR1 | |
| SCHEMBL1359525 | 0.81 | AGTR2 (0.52) | AGTR2 | |
| SCHEMBL708650 | 0.81 | AGTR2 (0.50) | AGTR2AGTR1 | |
| SCHEMBL708771 | 0.80 | AGTR2 (0.74) | AGTR2AGTR1 | |
| SCHEMBL710784 | 0.80 | AGTR2 (0.53) | AGTR2AGTR1 | |
| SCHEMBL707071 | 0.80 | AGTR2 (0.51) | AGTR2AGTR1 | |
| SCHEMBL24715469 | 0.79 | AGTR2 (0.67) | AGTR2AGTR1 | |
| SCHEMBL4194899 | 0.78 | AGTR2 (0.49) | AGTR2 | |
| SCHEMBL23120859 | 0.78 | AGTR2 (0.62) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124638-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-7652054-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2010-01-26 | — | — | US | disclosed |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | VICORE PHARMA AB | 2009-12-31 | — | — | US | disclosed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | AGTR2 2/4885AGTR1 1/4885 |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.